About a dozen of tech and biotech companies opted for the SPAC route this year, citing the expedited procedure and more certainty over the capital raise among the advantages of SPAC-ing over traditional initial public offerings. For Adam Sachs, CEO and co-founder of Vicarious Surgical, a key aspect of the process was the amount of due diligence that a SPAC sponsor can do — something that isn't typically possible in a conventional IPO, he said in an interview on Monday.